ImageneBio, Inc. SEC filings IMA

ImageneBio, Inc. has 336 filings in SEC EDGAR's recent list, going back to Jan 8, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 30, 2026 —
DEF 14A Proxy statement Apr 30, 2026 Jun 16, 2026
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 7, 2024
DEF 14A Proxy statement Sep 25, 2023 Oct 11, 2023
PRE 14A Preliminary proxy statement Sep 15, 2023 Sep 15, 2023
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 9, 2023
DEFA14A Additional proxy material Apr 27, 2022 —
DEF 14A Proxy statement Apr 27, 2022 Jun 9, 2022

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IMA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1835579
Former names
Ikena Oncology, Inc. (until Jul 25, 2025)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.